Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
Positive Phase II results on the first topical gene therapy sent a US biotech company’s share price up by 27% in Monday morning’s trading. 24 June 2019
Biotechnology
The US Food and Drug Administration has lifted the partial clinical hold placed on CANOVA (M13-494) in March this year, a Phase III trial evaluating venetoclax (trade named Venclexta and Venclyxto) for the investigational treatment of relapsed/refractory multiple myeloma. 24 June 2019
Biotechnology
Bristol-Myers Squibb has announced that, to help proceed its $74 billion acquisition of biotech major Celgene, it would sell one of the latter’s top-selling drugs, Otezla (apremilast). 24 June 2019
Biotechnology
New Jersey, USA-based drugmaker Bristol-Myers Squibb has announced a Phase III trial miss for Opdivo (nivolumab), with topline data showing the study did not meet its primary endpoint of overall survival (OS). 24 June 2019
Biotechnology
Vertex Pharmaceuticals continues to clock up regulatory approvals for its cystic fibrosis (CF) medicines. 24 June 2019
Biotechnology
In a filing with the US Securities and Exchange Commission (SEC), US biotech Exelixis has said it was informed last week by its collaboration partner Genentech, a US subsidiary of the Swiss pharma giant Roche, that the IMspire170 had failed to achieve pre-set goals. 24 June 2019
Biotechnology
Some eight months after gaining marketing clearance for the drug in the USA, and an April advisory committee recommendation in Europe, US pharma giant Pfizer has now also won approval for Talzenna (talazoparib) in the European Union. 24 June 2019
Biotechnology
The healthcare industry is at an inflection point with the market now preparing for more cell and gene therapies to be approved, writes Ana Stojanovska, vice president of Commercial Consulting at Xcenda, in an Expert View piece. 21 June 2019
Biotechnology
For Belgium-based drugmaker UCB, EULAR 2019 came at a good time to shed further new light on bimekizumab – which the company itself is billing as its pipeline molecule – in a couple of the indications in which it is showing significant promise. 21 June 2019
Biotechnology
The US cost-effectiveness group Institute for Clinical and Economic Review (ICER) yesterday released a Final Evidence Report assessing the comparative clinical effectiveness and value of Swiss pharma giant Novartis’ Mayzent (siponimod) for the treatment of secondary progressive multiple sclerosis (SPMS). 21 June 2019
Biotechnology
A Phase II proof-of-concept trial evaluating the investigational interleukin (IL)-33 antibody REGN3500 (SAR440340) met the primary endpoint of improvement in loss of asthma control when comparing REGN3500 monotherapy to placebo. 21 June 2019
Biotechnology
At its first investor day in five years, New Jersey, USA-based Merck & Co (NYSE: MRK) outlined key aspects of its clinical and commercial strategy, with chief executive Kenneth Frazier describing: “tremendous growth opportunities beyond Keytruda.” 21 June 2019
Biotechnology
Danish diabetes care giant Novo Nordisk announced late yesterday d that the European Commission has granted marketing authorization for Esperoct (turoctocog alfa pegol, N8-GP) for the treatment of adolescents (≥12 years of age) and adults with hemophilia A. 21 June 2019
Biotechnology
US gene therapy company Axovant Sciences has signed a strategic partnership with Yposkesi, a French contract development and manufacturing organization (CDMO). 20 June 2019
Biotechnology
US protein engineering company Codexis says that Casdin Capital, a New York City-based life science-focused investment firm and current stockholder of Codexis, has invested around $50 million in Codexis through the purchase of shares of Codexis’ common stock in a private placement. 20 June 2019
Biotechnology
Avacta Group, a developer of Affimer biotherapeutics and research reagents, has agreed a strategic partnership with the cell line development company Selexis. 20 June 2019
Biotechnology
US biotech major Amgen and the University of Washington's Institute for Protein Design (IPD) today announced a broad collaboration that will cover multiple projects with a goal of testing new technologies and creating protein-building approaches that can be broadly applied to the search for new medicines. 20 June 2019
Biotechnology
Japanese conglomerate Fujifilm Corp has signed an agreement to invest 300 million yen ($2.8 million) into a biotech venture, PuREC Co, through underwriting its third-party allocation of shares. 20 June 2019
Biotechnology
US biotech major Gilead Sciences has struck a deal with privately-held Nurix to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases. 19 June 2019
Biotechnology
Israeli oral drug delivery specialist Oramed Pharmaceuticals has provided an update regarding its ongoing clinical work. 19 June 2019
All news
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze